Transgenomic, Inc.

278 articles about Transgenomic, Inc.

• 

  As Liquid Biopsies Grow, Who's Going to Pay?

  9/20/2018

  Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.

• Precipio Diagnostics And Transgenomic, Inc. Complete Merger

  6/30/2017

• Transgenomic, Inc. Prepares For Planned Relisting On NASDAQ

  6/21/2017

• Precipio Diagnostics And Transgenomic, Inc. Announce Experts From Yale And Harvard Joining New Scientific Advisory Board To Support Merged Company’s Growth Initiatives

  6/16/2017

• European Patent Office Confirms Grant Of New ICE COLD-PCR Patent Exclusively Licensed To Transgenomic, Inc.

  6/13/2017

• Transgenomic, Inc. Stockholders And Precipio Diagnostics Members Approve Merger

  6/6/2017

• Transgenomic, Inc. Board Confirms Date And Location Of Special Meeting Of Stockholders And Announces Reverse Stock Split Ratio

  5/26/2017

• Transgenomic, Inc. Closes Bridge Financing

  4/17/2017

• Transgenomic, Inc. Provides Update On Its Planned Merger And Reports Change In Listing Status

  2/22/2017

• Transgenomic, Inc. Release: Company Announces Leading Clinical Laboratory Services Provider LifeLabs Selects ICE COLD-PCR As Its Mutation Enrichment Platform

  1/12/2017

• Transgenomic, Inc. And Precipio Diagnostics Announce Planned Merger

  10/13/2016

• Transgenomic, Inc. Adds New Distributors In China And India For Its ICEme Kits That Enable Liquid Biopsy Cancer Testing On Existing Platforms

  9/29/2016

• Transgenomic, Inc. And Ventana Medical Systems Complete Data Sharing Agreement

  9/22/2016

• Transgenomic, Inc. Reports Second Quarter 2016 Financial Results

  8/15/2016

• Transgenomic, Inc. To Hold Second Quarter 2016 Results Conference Call On August 12, 2016 At 5:00 PM EDT

  8/11/2016

• VWR To Distribute Transgenomic, Inc.’s ICEme Kits That Enable Liquid Biopsy-Based Cancer Research On Existing Platforms

  8/8/2016

• Transgenomic, Inc. Launches First Commercially Available CLIA Test For Detection Of EGFR C797S Mutations That Predict Resistance To 3rd Generation Kinase Therapies For Lung Cancer

  7/25/2016

• Transgenomic, Inc. Licenses Commercial Rights To Its Long QT Syndrome DNA Testing Portfolio To LabCorp

  7/20/2016

• Transgenomic, Inc. Accelerates Commercialization Of ICE COLD-PCR (ICP) Amid Plans To Expand Cancer Product Line Ten-Fold

  6/14/2016

• ASCO2016: Transgenomic, Inc. Releases New Data At ASCO 2016 Confirming Concordance Of ICE COLD-PCR (ICP) Liquid And Tissue Biopsies

  6/7/2016